文献速递神经肿瘤

重新审视儿童室管膜瘤:一项回顾性多中心分析揭示长期总生存不佳

Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.
PubMed 文献 · J Neurooncol · 2017-07-21

该回顾性多中心分析纳入103例WHO II/III级颅内室管膜瘤患儿及SEER数据库360例患者,中位随访11年,10年总生存(OS)为50±5%、无进展生存(PFS)为29±5%,SEER队列10年OS为52±3%,全切除(GTR)和II级病理与OS改善相关,但GTR者10年OS仅61±7%、PFS 36±6%,多数复发为室管膜瘤且74%位于原发部位,作者认为当前方案不足以长期治愈。

要点

  • 中位随访11年,10年OS为50±5%、PFS为29±5%,SEER队列10年OS为52±3%。
  • GTR和II级病理与OS显著改善相关,但GTR并非对所有儿童治愈。
  • GTR患者10年OS为61±7%、PFS为36±6%;74%复发位于原发部位。

核心结论

  • 当前治疗方案不足以长期治愈儿童室管膜瘤,作者认为亟需开发新的治疗方法。

研究设计与样本

  • 回顾性多中心分析,纳入1985年至2008年在Dana-Farber/波士顿儿童癌症与血液疾病中心和芝加哥Ann & Robert H. Lurie儿童医院治疗的103例WHO II/III级颅内室管膜瘤患儿,另从SEER数据库识别360例室管膜瘤患者。
  • 对机构队列采用log-rank检验及单因素和多因素Cox比例风险模型评估OS和PFS的临床及组织病理学预后因素,并与SEER队列的OS比较。

主要发现

  • 中位随访11年,10年OS为50±5%、PFS为29±5%。
  • SEER队列10年OS为52±3%。
  • GTR和II级病理与OS显著改善相关。
  • GTR患者10年OS为61±7%、PFS为36±6%。
  • 病理检查证实多数复发肿瘤为室管膜瘤,74%发生于原发肿瘤部位。

临床怎么用

  • 原文结论指出当前治疗方案不足以提供长期治愈,作者认为亟需开发新的治疗方法,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ependymoma is the third most common brain tumor in children, but there is a paucity of large studies with more than 10 years of follow-up examining the long-term survival and recurrence patterns of this disease. We conducted a retrospective chart review of 103 pediatric patients with WHO Grades II/III intracranial ependymoma, who were treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Chicago's Ann & Robert H. Lurie Children's Hospital between 1985 and 2008, and an additional 360 ependymoma patients identified from the Surveillance Epidemiology and End Results (SEER) database. For the institutional cohort, we evaluated clinical and histopathological prognostic factors of overall survival (OS) and progression-free survival (PFS) using the log-rank test, and univariate and multivariate Cox proportional-hazards models. Overall survival rates were compared to those of the SEER cohort. Median follow-up time was 11 years. Ten-year OS and PFS were 50 ± 5% and 29 ± 5%, respectively. Findings were validated in the independent SEER cohort, with 10-year OS rates of 52 ± 3%. GTR and grade II pathology were associated with significantly improved OS. However, GTR was not curative for all children. Ten-year OS for patients treated with a GTR was 61 ± 7% and PFS was 36 ± 6%. Pathological examination confirmed most recurrent tumors to be ependymoma, and 74% occurred at the primary tumor site. Current treatment paradigms are not sufficient to provide long-term cure for children with ependymoma. Our findings highlight the urgent need to develop novel treatment approaches for this devastating disease.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Marinoff AE, Ma C, Guo D, et al. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017. PMID: 28733870. doi:10.1007/s11060-017-2568-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。